These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1116154)

  • 1. The pharmacokinetics of 4-acetyl tritium vinblastine in two patients.
    Owellen RJ; Hartke CA
    Cancer Res; 1975 Apr; 35(4):975-80. PubMed ID: 1116154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological studies with vinblastine in the dog.
    Creasey WA; Scott AI; Wei CC; Kutcher J; Schwartz A; Marsh JC
    Cancer Res; 1975 May; 35(5):1116-20. PubMed ID: 1120303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of vinblastine in humans.
    Owellen RJ; Hartke CA; Hains FO
    Cancer Res; 1977 Aug; 37(8 Pt 1):2597-602. PubMed ID: 889590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The binding of vinblastine by platelets in the rat.
    Hebden HF; Hadfield JR; Beer CT
    Cancer Res; 1970 May; 30(5):1417-24. PubMed ID: 5426944
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA; Lucas VS
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of vindesine and vincristine in humans.
    Owellen RJ; Root MA; Hains FO
    Cancer Res; 1977 Aug; 37(8 Pt 1):2603-7. PubMed ID: 872088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
    Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
    Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.
    Lu K; Yap HY; Loo TL
    Cancer Res; 1983 Mar; 43(3):1405-8. PubMed ID: 6825110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance.
    Piekoszewski W; Chow FS; Jusko WJ
    Drug Metab Dispos; 1993; 21(4):690-8. PubMed ID: 7690698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and metabolism of Navelbine.
    Krikorian A; Rahmani R; Bromet M; Bore P; Cano JP
    Semin Oncol; 1989 Apr; 16(2 Suppl 4):21-5. PubMed ID: 2652317
    [No Abstract]   [Full Text] [Related]  

  • 12. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
    Spearman ME; Goodwin RM; Apelgren LD; Bumol TF
    J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
    Ericsson H; Hamrén B; Bergstrand S; Elebring M; Fryklund L; Heijer M; Ohman KP
    Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.
    Ohnuma T; Norton L; Andrejczuk A; Holland JF
    Cancer Res; 1985 Jan; 45(1):464-9. PubMed ID: 3965152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.
    Rosenblum MG; Murray JL; Haynie TP; Glenn HJ; Jahns MF; Benjamin RS; Frincke JM; Carlo DJ; Hersh EM
    Cancer Res; 1985 May; 45(5):2382-6. PubMed ID: 3986780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
    Osman S; Luthra SK; Brady F; Hume SP; Brown G; Harte RJ; Matthews JC; Denny WA; Baguley BC; Jones T; Price PM
    Cancer Res; 1997 Jun; 57(11):2172-80. PubMed ID: 9187117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine).
    Rahmani R; Martin M; Barbet J; Cano JP
    Cancer Res; 1984 Dec; 44(12 Pt 1):5609-13. PubMed ID: 6498821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: the basis of differential toxicity.
    Ferguson PJ; Cass CE
    Cancer Res; 1985 Nov; 45(11 Pt 1):5480-8. PubMed ID: 3863705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.